Vijaya Raj Bhatt
Overview
Explore the profile of Vijaya Raj Bhatt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
1598
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sureda A, Carpenter P, Bacigalupo A, Bhatt V, de la Fuente J, Ho A, et al.
Bone Marrow Transplant
. 2024 Mar;
59(6):832-837.
PMID: 38443706
Despite emergence of novel therapies to treat hematologic malignancies, allogeneic hematopoietic cell transplantation (allo-HCT) remains an essential treatment modality capable of curing these diseases. Allo-HCT has been also shown to...
12.
Dhakal P, Bhatt V
JCO Oncol Pract
. 2024 Jan;
20(3):311-313.
PMID: 38232338
This editorial and the accompanying article summarize evidence-based guidelines that can inform dietary recommendations in oncology practices.
13.
Bhatt V, Uy G, Klepin H
Blood
. 2023 Dec;
143(6):483-487.
PMID: 38048592
Determining fitness for intensive chemotherapy in an older adult with acute myeloid leukemia (AML) is an unanswered age-old question. Geriatric assessment captures any variation in multidimensional health, which can influence...
14.
Murthy H, Zhang M, Chen K, Ahmed S, Deotare U, Ganguly S, et al.
Blood Adv
. 2023 Oct;
7(22):7007-7016.
PMID: 37792849
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT)...
15.
Chaaban S, Zimmer A, Bhatt V, Schmidt C, Sadikot R
Pathogens
. 2023 May;
12(5).
PMID: 37242396
Allogeneic stem cell transplantation is a lifesaving treatment for many malignancies. Post-transplant patients may suffer from graft versus host disease in the acute and/or the chronic form(s). Post-transplantation immune deficiency...
16.
Bhatt V, Ulrich A, Uy G, Stone R, Stock W, Ojelabi M, et al.
JCO Oncol Pract
. 2023 Apr;
19(6):e877-e891.
PMID: 37058684
Purpose: Clinical trials are important for managing older patients with AML. We investigated differences in outcomes of older patients with AML on the basis of whether patients participated in intensive...
17.
Narayan R, Niroula A, Wang T, Kuxhausen M, He M, Meyer E, et al.
Transplant Cell Ther
. 2023 Mar;
29(7):452.e1-452.e11.
PMID: 36997024
Mutation-bearing peptide ligands from mutated nucleophosmin-1 (NPM1) protein have been empirically found to be presented by HLA class I in acute myeloid leukemia (AML). We hypothesized that HLA genotype may...
18.
Boyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, et al.
Leukemia
. 2023 Mar;
37(5):1173.
PMID: 36949156
No abstract available.
19.
Marar R, Abbasi M, Prathivadhi-Bhayankaram S, Daryanani A, Villarraga H, Anavekar N, et al.
JCO Oncol Pract
. 2023 Mar;
19(6):331-342.
PMID: 36930845
The field of malignant hematology is transforming with novel immunotherapeutic approaches. Unfortunately, quality of life, treatment efficacy, and life expectancy are negatively affected by cardiotoxic side effects of treatment. To...
20.
Dhakal P, Lyden E, Joshi U, Pyakuryal A, Loh K, Klepin H, et al.
Leuk Lymphoma
. 2023 Jan;
64(3):691-697.
PMID: 36629003
Association between comorbidity burden and patient outcomes has not been adequately investigated in acute promyelocytic leukemia (APL). We utilized the National Cancer Database to evaluate the association of the Charlson-Deyo...